WebMar 22, 2024 · Flare Therapeutics Inc. raised $123 million in an oversubscribed series B round to take its lead compound, FX-909, a potentially first-in-class peroxisome … WebMar 22, 2024 · Their most recent investment was on Mar 22, 2024, when Flare Therapeutics raised $123M. Boxer Capital has made 23 diversity investments. Their most recent diversity investment was on Sep 7, 2024, when SpringWorks Therapeutics raised $225M. Boxer Capital has had 54 exits. Boxer Capital 's most notable exits include …

List of top East Coast Biopharma Companies - Crunchbase

WebTop Funding Types Series A , Series B , Grant , Convertible Note , Debt Financing Early stage venture funding includes Series A and Series B rounds. This list of companies and startups in the biopharma space with early stage venture funding provides data on their funding history, investment activities, and acquisition trends. WebMar 22, 2024 · Flare Therapeutics's latest funding round was a Series B for $123M on March 22, 2024. View all funding This profile has not been claimed. You're more than your latest funding, tell our customers your company's story. Submit Your Analyst Briefing Flare Therapeutics Investors 14 Investors Flare Therapeutics has 14 investors. how much is home help per hour

About - Flare Therapeutics Flare Therapeutics

WebMar 22, 2024 · Cambridge, MA – March 22, 2024 – Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for … WebMar 22, 2024 · Flare Therapeutics closed an oversubscribed Series B funding round Wednesday counting $123 million in earnings, which it will use to advance FX-909, its … how do genetic tests work